Genexine Inc., of Seoul, South Korea, said the FDA granted orphan drug designation to GX-H9 to treat growth hormone deficiency. The next-generation recombinant human growth hormone is being studied in once-weekly and twice-monthly dosing schedules. The company is scheduled to present data this weekend in Tokyo at the 9th Biennial Asia Pacific Pediatric Endocrinology Society/50th Annual Japanese Society for Pediatric Endocrine Society Conference.